Creating engineered exosomes to improve pancreatic cancer treatment
Engineering Exosome for Pancreatic Cancer Targeting Therapies
This study is looking at a new way to help treat pancreatic cancer by using tiny particles called exosomes to deliver medicine directly to the cancer cells, which could make treatments work better for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Toledo Health Sci Campus NIH-funded |
| Lab location | 1 site (Toledo, United States) |
| Project ID | NIH-10932982 on NIH RePORTER |
What this research studies
This research focuses on developing engineered exosomes as a novel delivery system for therapies targeting pancreatic cancer. By modifying the surface of exosomes with specific peptides, the researchers aim to enhance their ability to target cancer cells while minimizing clearance by the immune system. The approach involves using exosomes to deliver drugs and genetic material directly to tumor cells, potentially improving treatment efficacy. Patients may benefit from more effective therapies that can better reach and treat pancreatic cancer cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma who are seeking innovative treatment options.
Not a fit: Patients with other types of cancer or those who are not diagnosed with pancreatic cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, improving survival rates and quality of life for patients.
How similar studies have performed: Other research has shown promise in using engineered exosomes for targeted drug delivery, indicating that this approach may be viable.
Where this research is happening
Toledo, United States
- University of Toledo Health Sci Campus — Toledo, United States (Active)
Researchers
- Principal investigator: Liu, Shi-He — University of Toledo Health Sci Campus
- Study coordinator: Liu, Shi-He
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.